Prespecified secondary analysis of the pooled STEP-HFpEF trials finds semaglutide 2.4 mg improves heart failure symptoms similarly in women and men, with greater weight loss in women. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial shows once-weekly semaglutide produced a placebo-subtracted weight reduction of 10.2% sustained to 208 weeks in adults with cardiovascular disease and overweight or obesity but without diabetes. PICO summary and expert commentary.
A pre-specified analysis of the SELECT trial assessing whether once-weekly semaglutide 2.4 mg improves kidney outcomes in adults with overweight or obesity and cardiovascular disease, without diabetes. PICO summary and expert commentary.
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
A prespecified secondary analysis of the STEP-HFpEF programme found that once-weekly semaglutide 2.4 mg lowered NT-proBNP and produced larger symptom gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the SURPASS program found tirzepatide produced similar HbA1c, weight, and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40. PICO summary and expert commentary.
A published study protocol for a 52-week double-blind randomised trial of semaglutide plus empagliflozin versus each drug alone for NAFLD in type 2 diabetes. No efficacy results are reported yet. PICO summary and expert commentary.